

**AB SCIENCE S.A.**

Public limited company with a capital of 591 701,53 euros

Head office: 3, avenue George V, 75008 PARIS

438 479 941 RCS Paris

**MONTHLY REPORT ON THE AB SCIENCE TOTAL NUMBER OF VOTING RIGHTS AND SHARES**

*Article 221-1 and 223-16 of the Règlement Général de l'Autorité des Marchés Financiers*

**ISIN Code:** FR0010557264

Status: June 30, 2024

<b>Share Classes</b>	<b>Total number of outstanding shares</b>	<b>Total number of voting rights</b>
Ordinary shares	52,375,019	69,201,786
Class B Preferred Shares <sup>(1)</sup>	45,134	0
Class D Preferred Shares <sup>(2)</sup>	6,000,000	0
Class E Preferred Shares <sup>(3)</sup>	750,000	0

- (1) *The terms and conditions of the Class B Preferred Shares are set forth in paragraphs II and III of article 11 of the AB Science by-laws. Without the following description being exhaustive, the Class B Preferred Shares will only confer upon their holders financial and voting rights at ordinary and extraordinary shareholders' meetings as from the day they become convertible into ordinary shares, i.e. January 1, 2025 (the conversion being dependent on criteria related to operational objectives and the evolution of the share price).*
- (2) *The terms and conditions of the Class D Preferred Shares are set forth in paragraphs V and VI of Article 11 of the AB Science by-laws. Without the following description being exhaustive, the Class D Preferred Shares shall not confer upon their holders any voting or financial rights until AB Science has obtained two marketing approvals (from the European Medicines Agency or the U.S. Food and Drug Administration) for one or more of its drug candidates in two different indications, such two marketing approvals to be obtained no later than December 31, 2030.*
- (3) *Without the following description being exhaustive, until they are converted into ordinary shares, the Class E Preference Shares will not confer any voting rights, but they will benefit from a preferential dividend right equal, up to a total limit of 9.0 million euros, to the following amounts: (i) 1.25% of masitinib net sales, excluding any milestones and upfronts under a licensing agreement, and (ii) 1.25% of any upfronts and milestones.*

Paris, July 12, 2024